Cargando…

Monitoring NK cell activity in patients with hematological malignancies

Natural killer (NK) cells are lymphocytes of the innate immune system that can recognize and kill various types of malignant cells. Monitoring the activity of peripheral NK cells in patients affected by hematological malignancies may provide prognostic information or unveil ongoing tumor-specific im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viel, Sébastien, Charrier, Emily, Marçais, Antoine, Rouzaire, Paul, Bienvenu, Jacques, Karlin, Lionel, Salles, Gilles, Walzer, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850490/ https://www.ncbi.nlm.nih.gov/pubmed/24327939 http://dx.doi.org/10.4161/onci.26011

Ejemplares similares

One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy
por: Besson, Laurie, et al.
Publicado: (2018)

Regulation of Mouse NK Cell Development and Function by Cytokines
por: Marçais, Antoine, et al.
Publicado: (2013)

The metabolic checkpoint kinase mTOR is essential for interleukin-15 signaling during NK cell development and activation
por: Marçais, Antoine, et al.
Publicado: (2014)

Activation of Natural Killer Cells in Patients with Chronic Bone and Joint Infection due to Staphylococci Expressing or Not the Small Colony Variant Phenotype
por: Viel, Sébastien, et al.
Publicado: (2014)

Regulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells
por: Viel, Sébastien, et al.
Publicado: (2017)

NK Cells in the Treatment of Hematological Malignancies
por: Gonzalez-Rodriguez, Ana P, et al.
Publicado: (2019)

Signaling Pathways Leading to mTOR Activation Downstream Cytokine Receptors in Lymphocytes in Health and Disease
por: Fallone, Lucie, et al.
Publicado: (2023)

NK Cell-Based Immunotherapy for Hematological Malignancies
por: Sivori, Simona, et al.
Publicado: (2019)

CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
por: Xu, Kai-lin, et al.
Publicado: (2019)

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies
por: Shimizu, Kanako, et al.
Publicado: (2020)

Abstract 2 Development of CAR-NK Cell Therapy for Hematologic Malignancies
por: Stoltzman, Carrie, et al.
Publicado: (2022)

T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow
por: Daussy, Cécile, et al.
Publicado: (2014)

Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection
por: van Helden, Mary J., et al.
Publicado: (2015)

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
por: Vey, Norbert, et al.
Publicado: (2018)

Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
por: Tumino, Nicola, et al.
Publicado: (2021)

A NK Cell Odyssey: From Bench to Therapeutics Against Hematological Malignancies
por: Ramos-Mejia, Veronica, et al.
Publicado: (2022)

Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants
por: Koenig, Alice, et al.
Publicado: (2019)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
por: Marofi, Faroogh, et al.
Publicado: (2021)

CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
por: Huang, Ruihao, et al.
Publicado: (2023)

High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors
por: Marçais, Antoine, et al.
Publicado: (2017)

Editorial: TGF-β as a Key Regulator of NK and ILCs Development and Functions
por: Bottino, Cristina, et al.
Publicado: (2021)

Sensitisation to Cor a 14 and Cor a 9 is a risk marker for severe hazelnut allergy in children
por: Garnier, Lorna, et al.
Publicado: (2014)

Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications
por: Farnault, Laure, et al.
Publicado: (2012)

A multifaceted approach targeting NK cells for better treatment of cancer: focus on hematological malignancies
por: Kim, Hun Sik
Publicado: (2015)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
por: Salles, Gilles, et al.
Publicado: (2017)

Could a defective epithelial sodium channel lead to bronchiectasis
por: Fajac, Isabelle, et al.
Publicado: (2008)

Peripheral natural killer cells in chronic hepatitis B patients display multiple molecular features of T cell exhaustion
por: Marotel, Marie, et al.
Publicado: (2021)

Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies
por: Coccaro, Nicoletta, et al.
Publicado: (2020)

Novel immune modulators used in hematology: impact on NK cells
por: Krieg, Stephanie, et al.
Publicado: (2013)

Late‐onset hemophagocytic lymphohistiocytosis with neurological presentation
por: Benezech, Sarah, et al.
Publicado: (2017)

Dissecting the NK Cell Population in Hematological Cancers Confirms the Presence of Tumor Cells and Their Impact on NK Population Function
por: Vo, Dang-Nghiem, et al.
Publicado: (2020)

Carbamazepine and Hematological Malignancies
por: Yavaşoğlu, İrfan, et al.
Publicado: (2013)

Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies
por: Hayette, Sandrine, et al.
Publicado: (2021)

Malignant benign hematology
por: Sholzberg, Michelle
Publicado: (2018)

Neoantigens in Hematologic Malignancies
por: Biernacki, Melinda A., et al.
Publicado: (2020)

Deubiquitinases in hematological malignancies
por: Lei, Hu, et al.
Publicado: (2021)

Autophagy in Hematological Malignancies
por: García Ruiz, Olga, et al.
Publicado: (2022)

A Case of Type 2 Hypersensitivity to Rasburicase Diagnosed with a Natural Killer Cell Activation Assay
por: Viel, Sébastien, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_am4b2radhs31n2qfku9fe8pb8p